Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics

被引：32

作者：

Hursey, M ^{[1
]}

Newton, DL ^{[1
]}

Hansen, HJ ^{[1
]}

Ruby, D ^{[1
]}

Goldenberg, DM ^{[1
]}

Rybak, SM ^{[1
]}

机构：

[1] NCI, Div Canc Treatment & Diag, Dev Therapeut Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA

来源：

LEUKEMIA & LYMPHOMA | 2002年 / 43卷 / 05期

关键词：

antibody; ribonuclease; cancer; immunotoxin; apoptosis; CD22;

D O I：

10.1080/10428190290021380

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeting CD22 on human B-cells with a monoclonal antibody conjugated to a cytotoxic RNAse causes potent and specific killing of the lymphoma cells in vitro. This translates to anti-tumor effects in human lymphoma models in SCID mice. RNA damage caused by RNAses could be an important alternative to standard DNA-damaging chemotherapeutics. A second generation construct with an improved recombinant cytotoxic RNAse is described. Targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant or bacterial toxin-containing immunoconjugates.

引用

页码：953 / 959

页数：7

共 49 条

[21]

LEONARD JP, 2000, CANCER BIOTHER RADI, V15, P104

[22] THE EPITOPE SPECIFICITY AND TISSUE REACTIVITY OF 4 MURINE MONOCLONAL ANTI-CD22 ANTIBODIES [J].